For example, targeting the PI3K-AKT pathway using the PI3K inhibitor duvelisib in combination with R-CHOP was proven to suppress the tumor growth in CHO resistant DLBCL cells [53]. Here, AKT1 is linked to diffuse large B-cell lymphoma.